Default company panoramic image

Elute, Inc.

Drug-releasing bone void fillers that prevent orthopedic infection and promote bone healing.

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Salt Lake City, UT, USA
  • Currency USD
  • Founded October 2011
  • Employees 7
  • Website

Company Summary

Elute, Inc. aims to be the leader in the development and commercialization of a new class of patented and patent pending drug eluting devices designed for controlled and sustained release of drugs aimed at preventing and treating bone infections. Elute’s products provide a clinically relevant delivery of antibiotics and other therapeutic agents directly into surgical sites of patients undergoing orthopedic procedures. Elute's first product candidate, ElutiBoneTM, has shown in in-vitro tests the controlled release of certain antibiotics in a therapeutic range for a 7-8 week period. Furthermore, animal studies confirm that ElutiBone eliminates pathogens in vivo, while preventing infection in large and small animal peri-operative infection models while simultaneously enhancing bone formation.


  • Default avatar
    David W. Grainger, PhD
    Chief Scientific Officer & Board of Directors

    Chair Pharmaceutics & Pharmaceutical Chemistry. Professor of Pharmaceutical Chemistry and Bioengineering, University of Utah. Scientific Advisor AO Foundation & Synthes.

  • Default avatar
    Dennis B. Farrar
    Chairman, Board of Directors

    Founding partner fo UpStart Ventures in Salt Lake City, Utah. Cofounder fo 13 life sciences companies, including Myriad Genetics (MYGN) and SerePrognostics ( He also cofounded Utah Ventures, Utah's first institutionally-financed venture fund. Mr. Farrar is a graduate of Stanford University and Stanford Law School and has practiced law with large firms in New York, San Francisco and Salt Lake City.

  • Default avatar
    Philip A. Davidson, MD
    Board of Directors

    Partner, Heiden Davidson Orthopaedics, Park City, UT (joint resurfacing and replacement, sports medicine).
    Consultant with early stage orthopedic companies.

  • Default avatar
    Cheryl R. Blanchard, PhD
    Board of Directors

    20+ years of experience with orthopedic device companies.
    Former Chief Science Officer and Sr. Vice President of Zimmer Holdings (world's largest orthopedic company). Currently, CEO of BioCHIPS.

  • Default avatar
    Ashok C Khandkar

    Ashok Khandkar joined the Company’s Board of Directors in December 2011 and serves as the CEO. He was the founding CEO of Amedica (Nasdaq, AMDA), an orthopedic company, from '00 - '09. In 2010, he founded Bloxr, (sold in Sept. 2014). He consults with a startup focused on a novel laparoscopy platform. He has over 27 years of experience in founding and leading companies. He earned his Ph.D. in Materials Science from Arizona State University.

  • Eaa12f61 c7c8 44f8 9c05 e7556cc415b2
    VP Research & Development

    He is the VP R&D. He has over 20 years of experience in development and commercialization of biomaterials and drug delivery technologies. Prior to that, he was VP R&D at Histogenics, where he helped raise $49 million in funding. Previously he was the CTO of ProChon Biotech and CSO of Curative Bioscience. At Inion as VP R&D, he helped lead Inion's $75 million IPO. He earned his Ph.D. in Bioengineering from the University of Utah in 1990.


  • Default avatar
    Bruce Sunstein, Esq., Sunstein Kann Murphy & Timbers, Boston
    4f8484e4 efb1 44e6 b1c6 5d47780a0845
    Default avatar
    Don Urbanowicz

Previous Investors

  • Default avatar
    UpStart Ventures
    Default avatar
    JIS Ventures
    Default avatar
    University of Utah Research Foundation